$125M Stock Offering Launched as Cash-Strapped Gene Editor Faces Going Concern
PRME sits 43% above its 52-week low of $2.67.
Summary
Prime Medicine launched a $125.0 million underwritten common stock offering, with a 30-day option for up to $18.75 million more. That is a large raise for a company whose cash stood at $95.1 million at the end of Q2 2026, when its 10-Q carried a going concern warning and management said it needed to raise capital. The deal is being run by Jefferies, TD Cowen and Goldman Sachs under the existing shelf, so dilution is the immediate issue for holders. Pricing terms are not yet set; the final size and discount will come with the prospectus supplement. The raise buys runway for the pipeline, which includes PM647 (FDA IND clearance in September) and the PM577a Wilson's disease program that dosed its first patient in October.
At the time of this announcement, PRME was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $707.4M. The 52-week trading range was $2.67 to $5.91. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.